Becton Dickinson and Co (BDX) Holdings Lessened by Private Advisor Group LLC

Private Advisor Group LLC trimmed its holdings in Becton Dickinson and Co (NYSE:BDX) by 66.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,023 shares of the medical instruments supplier’s stock after selling 17,508 shares during the period. Private Advisor Group LLC’s holdings in Becton Dickinson and were worth $2,355,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in BDX. Acropolis Investment Management LLC acquired a new position in shares of Becton Dickinson and in the 3rd quarter valued at approximately $101,000. Almanack Investment Partners LLC. acquired a new position in shares of Becton Dickinson and in the 2nd quarter valued at approximately $105,000. Truvestments Capital LLC acquired a new position in shares of Becton Dickinson and in the 3rd quarter valued at approximately $105,000. Bartlett & Co. LLC raised its position in shares of Becton Dickinson and by 2,900.0% in the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 435 shares in the last quarter. Finally, Bridgeworth LLC acquired a new position in shares of Becton Dickinson and in the 2nd quarter valued at approximately $131,000. 92.60% of the stock is currently owned by institutional investors.

In related news, Director Timothy M. Ring sold 42,000 shares of the company’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the completion of the transaction, the director now directly owns 93,688 shares in the company, valued at approximately $22,210,614.16. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP James C. Lim sold 5,189 shares of the company’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $242.36, for a total value of $1,257,606.04. Following the transaction, the executive vice president now owns 13,318 shares of the company’s stock, valued at $3,227,750.48. The disclosure for this sale can be found here. 1.00% of the stock is owned by corporate insiders.

A number of brokerages have recently weighed in on BDX. Wells Fargo & Co boosted their price target on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Piper Jaffray Companies lowered their price target on Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a report on Tuesday, November 6th. Royal Bank of Canada reiterated a “hold” rating and issued a $248.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Barclays began coverage on Becton Dickinson and in a report on Monday, October 15th. They issued an “equal weight” rating and a $278.00 price target for the company. Finally, Citigroup boosted their price target on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $254.07.

Shares of BDX opened at $243.26 on Friday. The firm has a market cap of $65.41 billion, a P/E ratio of 22.09, a P/E/G ratio of 1.68 and a beta of 1.19. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. Becton Dickinson and Co has a 12 month low of $209.91 and a 12 month high of $265.87.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, hitting the Zacks’ consensus estimate of $2.93. The firm had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm’s revenue was up 39.0% on a year-over-year basis. During the same period in the prior year, the business earned $2.40 EPS. On average, equities analysts forecast that Becton Dickinson and Co will post 12.2 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.wkrb13.com/2018/11/11/becton-dickinson-and-co-bdx-holdings-lessened-by-private-advisor-group-llc.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Further Reading: What are the Different Types of Leveraged Buyouts?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply